Guardant Health Posts 39% Revenue Surge in Q4 2025, Eyes 27-30% Growth in 2026
Event summary
- Guardant Health reported $281.3M in Q4 2025 revenue, up 39% YoY, with oncology tests growing 38% to 79,000.
- Full-year 2025 revenue hit $982M, a 33% increase, with non-GAAP gross margin improving to 66% from 62%.
- 2026 guidance projects $1.25B-$1.28B in revenue, with screening revenue expected to quadruple to $162M-$174M.
- Completed $59M acquisition of MetaSight Diagnostics and secured $327.3M from a November 2025 stock offering.
- Strategic collaboration with Merck for companion diagnostics and cancer therapy commercialization.
The big picture
Guardant Health's strong 2025 performance underscores the growing demand for liquid biopsy and precision oncology solutions. The company's strategic moves—including the Merck partnership and MetaSight acquisition—position it to capitalize on trends in early cancer detection and therapy monitoring. With $1.3B in cash reserves and improving operational efficiency, Guardant is well-funded to execute its growth plans, though scaling commercial teams and integrating acquisitions will be key challenges.
What we're watching
- Revenue Diversification
- Whether Guardant can sustain rapid growth across oncology, biopharma, and screening segments simultaneously.
- Operational Scaling
- The pace at which Guardant integrates MetaSight Diagnostics and expands commercial infrastructure to support demand.
- Regulatory Approvals
- How quickly Guardant Reveal chemotherapy monitoring gains Medicare reimbursement through MolDx.
Related topics